According to a large-scale study published in The BMJ, GLP-1 class medications (such as Ozempic and Wegovy) are effective not only for diabetes and weight loss but also for combating various harmful habits and addictions. Scientists suggest that these drugs target biological pathways in the brain that are common to all types of addiction.
Study Results
A team from the University of Washington analyzed data from more than 600,000 patients. The study revealed that taking GLP-1 medications significantly reduces the risk of developing addictions to all major substances:
-
Opioids: 25% reduction in risk;
-
Cocaine and Nicotine: 20% reduction in risk;
-
Alcohol: 18% reduction in risk;
-
Cannabis: 14% reduction in risk.
While existing treatment methods have traditionally focused on one specific substance (for example, nicotine patches focusing solely on smoking cessation), GLP-1 drugs directly affect the “craving” mechanism itself.
Patients who noted the disappearance of “constant food noise” during weight loss experience a similar effect toward other harmful substances. The medication appears to suppress the very urges that drive a person toward addiction.
The study showed particularly promising results in patients who had already developed a dependency. After three years of observation, GLP-1 users saw:
-
A 40% decrease in overdose cases;
-
A 50% reduction in drug-related mortality;
-
A significant decline in the need for hospitalization and emergency care.
Scientists hope that future clinical trials will establish GLP-1 as an official standard for addiction treatment.
